4564 fundamentals

OncoTherapy Science, Inc. engages in the research and development of antibody drugs. The firm operates through the following business segments: Drug Research and Development and Related Business, and Cancer Precision Medicine Related Business. The Drug Research and Development and Related Business segment includes drug discovery research in various fields, such as small molecule drugs, cancer peptide vaccines, and antibody drugs, and clinical trials based on the results of drug discovery research. The Cancer Precision Medicine Related Business segment engages in joint research and commercialization of detailed genetic analysis services of cancer cells (whole genome sequence analysis, neoantigen analysis, neoantigen dendritic cell therapy, etc.), large-scale analysis tests of cancer genes such as liquid biopsy for the early detection of cancer cells in the blood, as well as analysis services such as TCR/BCR repertoire analysis and immune response analysis. The company was founded on April 6, 2001 and is headquartered in Kawasaki, Japan.